Elon Musk Signs Australian Pact... Sends One Company Soaring Overnight
Tesla is facing a critical lithium shortage. Could this company be the next Tesla savior?
Click Here To Get The Full Story

MNPR Insider Trading (Monopar Therapeutics)

Insider Ownership Percentage: 41.50%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,830,000.00

Monopar Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Monopar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Monopar Therapeutics Share Price & Price History

Current Price: $6.25
Price Change: Price Increase of +0.24 (3.99%)
As of 06/24/2021 11:18 AM ET

This chart shows the closing price history over time for MNPR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Elon Musk Signs Australian Pact... Sends One Company Soaring Overnight
Tesla is facing a critical lithium shortage. Could this company be the next Tesla savior?
Click Here To Get The Full Story

Monopar Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/11/2021Tactic Pharma LlcMajor ShareholderSell125,000$14.64$1,830,000.00View SEC Filing Icon  
See Full Table
Insider Trading at Monopar Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Monopar Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Monopar Therapeutics (NASDAQ:MNPR)

1.54% of Monopar Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MNPR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Monopar Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/21/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC12,479$77K0.0%N/A0.099%Search for SEC Filing on Google Icon
5/17/2021Royal Bank of Canada9,130$57K0.0%N/A0.073%Search for SEC Filing on Google Icon
5/12/2021Northern Trust Corp36,001$0.22M0.0%-38.8%0.286%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC26,394$0.16M0.0%N/A0.210%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.11,229$70K0.0%+108.3%0.089%Search for SEC Filing on Google Icon
2/11/2021Northern Trust Corp58,793$0.36M0.0%-9.2%0.513%Search for SEC Filing on Google Icon
2/5/2021BlackRock Inc.5,391$33K0.0%+99.4%0.047%Search for SEC Filing on Google Icon
2/10/2020Bank of Montreal Can13,000$0.22M0.0%N/A0.123%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Monopar Therapeutics logo
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.
Read More on Monopar Therapeutics

Today's Range

Now: $6.25
Low: $6.25
High: $6.96

50 Day Range

MA: $5.68
Low: $5.05
High: $6.30

52 Week Range

Now: $6.25
Low: $4.28
High: $17.01

Volume

449 shs

Average Volume

169,583 shs

Market Capitalization

$78.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Who are the company insiders with the largest holdings of Monopar Therapeutics?

Monopar Therapeutics' top insider investors include:
  1. Tactic Pharma Llc (Major Shareholder)

Who are the major institutional investors of Monopar Therapeutics?

Monopar Therapeutics' top institutional shareholders include:
  1. Northern Trust Corp — 0.29%
  2. Geode Capital Management LLC — 0.21%
  3. Citadel Advisors LLC — 0.10%
  4. Citadel Advisors LLC — 0.10%
  5. BlackRock Inc. — 0.09%
  6. Royal Bank of Canada — 0.07%

Which major investors are selling Monopar Therapeutics stock?

In the previous quarter, MNPR stock was sold by these institutional investors:
  1. Northern Trust Corp

Which major investors are buying Monopar Therapeutics stock?

In the previous quarter, MNPR stock was bought by institutional investors including:
  1. Geode Capital Management LLC
  2. Citadel Advisors LLC
  3. Citadel Advisors LLC
  4. Royal Bank of Canada
  5. BlackRock Inc.
Elon Musk Signs Australian Pact... Sends One Company Soaring Overnight
Tesla is facing a critical lithium shortage. Could this company be the next Tesla savior?
Click Here To Get The Full Story